Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target

被引:1
|
作者
Dattani, Abhishek [1 ]
Singh, Anvesha
Mccann, Gerry P.
Gulsin, Gaurav S.
机构
[1] Univ Leicester, Dept Cardiovasc Sci, Leicester LE3 9QP, England
关键词
diabetes; calcium handling; manganese-enhanced MRI; GLYCATION END-PRODUCTS; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONGESTIVE-HEART-FAILURE; DIASTOLIC DYSFUNCTION; VENTRICULAR MYOCYTES; CARDIAC STRUCTURE; GENE-EXPRESSION; MANGANESE IONS; YOUNG-ADULTS; CARDIOMYOPATHY;
D O I
10.3390/jcdd11010012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes (T2D) is a multisystem disease with rapidly increasing global prevalence. Heart failure has emerged as a major complication of T2D. Dysregulated myocardial calcium handling is evident in the failing heart and this may be a key driver of cardiomyopathy in T2D, but until recently this has only been demonstrated in animal models. In this review, we describe the physiological concepts behind calcium handling within the cardiomyocyte and the application of novel imaging techniques for the quantification of myocardial calcium uptake. We take an in-depth look at the evidence for the impairment of calcium handling in T2D using pre-clinical models as well as in vivo studies, following which we discuss potential novel therapeutic approaches targeting dysregulated myocardial calcium handling in T2D.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] PGC-1 activation: a therapeutic target for type 2 diabetes?
    Yuan, Daixiu
    Xiao, Dingfu
    Gao, Qian
    Zeng, Liming
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2019, 24 (03) : 385 - 395
  • [32] NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?
    Liu, Shan-Shan
    Ding, Ye
    Lou, Ji-Quan
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (04) : 391 - 392
  • [33] NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?
    Shan-Shan Liu
    Ye Ding
    Ji-Quan Lou
    Cardiovascular Drugs and Therapy, 2014, 28 : 391 - 392
  • [34] PGC-1α activation: a therapeutic target for type 2 diabetes?
    Daixiu Yuan
    Dingfu Xiao
    Qian Gao
    Liming Zeng
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2019, 24 : 385 - 395
  • [35] The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
    Porter, Karen E.
    Riches, Kirsten
    CLINICAL SCIENCE, 2013, 125 (3-4) : 167 - 182
  • [36] Novel hormone potential new target in Type 2 diabetes
    Patel, Jitesh
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (04) : 321 - 321
  • [37] Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes
    Chen, Rong-Bin
    Wang, Qi-Yu
    Wang, Yuan-Yuan
    Wang, Ya-Di
    Liu, Jiang-Hua
    Liao, Zhe-Zhen
    Xiao, Xin-Hua
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [38] Novel Clusters of Type 2 Diabetes: A Tailored Therapeutic Approach
    Duarte, Vitoria
    Ivo, Catarina
    Verissimo, David
    Silva, Joao
    Lopes, Luis
    Passos, Dolores
    de Castro, Joao Jacome
    Marcelino, Mafalda
    REVISTA PORTUGUESA DE ENDOCRINOLOGIA DIABETES E METABOLISMO, 2020, 15 (3-4) : 109 - 113
  • [39] Lipocalin-2 as a therapeutic target for bone fragility as a type 2 diabetes complication
    Solis-Suarz, D. L.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [40] SGLT2 inhibitors : kidney as a new therapeutic target for type 2 diabetes
    Bons, Justine
    Prevost, Gaetan
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (07): : 191 - 195